The Basic Traditional Treatments for Lyme Disease

Dr. Schaller’s Perspective: Dr. Schaller does not agree with the traditional IDSA approach to treating Lyme disease. He believes this approach failed members of his own family, and the following article explains his perspective on alternative treatment considerations.

Lyme disease does not have 60 equally validated antimicrobial treatments. To make a useful top-60 list, I’ll include established antibiotic regimens, manifestation-specific management, prevention/reinfection strategies, management of complications, and investigational approaches—clearly labeling the evidence.

Current CDC guidance says most early Lyme disease is successfully treated with 10–14 days of antibiotics, most commonly doxycycline, amoxicillin, or cefuroxime axetil. The IDSA/AAN/ACR guideline is reaffirmed by the American Academy of Neurology.

Top 60 Lyme disease treatments and management approaches

1. Doxycycline — first-line oral therapy for erythema migrans (EM).
2. Amoxicillin — first-line oral alternative for EM.
3. Cefuroxime axetil — first-line oral alternative for EM.
4. Azithromycin — second-line option when doxycycline and beta-lactams cannot be used.
5. 10-day doxycycline course for EM — guideline-supported regimen.
6. 14-day amoxicillin course for EM — guideline-supported regimen.
7. 14-day cefuroxime course for EM — guideline-supported regimen.
8. Azithromycin course for EM — generally 5–10 days; 7 days preferred in the U.S. guideline when used.
9. Treatment based on clinical EM diagnosis — a classic EM lesion does not require waiting for serology before treatment.
10. Early treatment of disseminated Lyme disease — antibiotic selection depends on neurologic, cardiac and other involvement.

Reference for 1–10: Lantos PM, et al. Clinical Practice Guidelines by IDSA, AAN, and ACR: 2020 Guidelines for Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021;72:e1-e48.

11. Oral doxycycline for Lyme meningitis — one guideline-supported option in appropriate patients.
12. IV ceftriaxone for Lyme meningitis.
13. IV cefotaxime for Lyme meningitis.
14. IV penicillin G for Lyme meningitis.
15. Doxycycline for Lyme cranial neuropathy, including appropriate cases of facial nerve palsy.
16. Ceftriaxone for neurologic Lyme disease when IV treatment is selected.
17. Cefotaxime for neurologic Lyme disease.
18. Penicillin G for neurologic Lyme disease.
19. Doxycycline for Lyme radiculoneuropathy in appropriate cases.
20. 14–21 days of antimicrobial therapy for many acute neurologic manifestations.

The guideline considers doxycycline, ceftriaxone, cefotaxime and penicillin G appropriate choices for meningitis, cranial neuropathy, radiculoneuropathy and other peripheral nervous-system manifestations, with route individualized to the clinical situation.

21. IV therapy for Lyme encephalomyelitis/parenchymal CNS disease — preferred over oral therapy when Lyme directly involves brain or spinal-cord parenchyma.
22. IV ceftriaxone for severe neurologic Lyme disease.
23. IV-to-oral step-down therapy when clinically appropriate.
24. Treatment of Lyme-associated facial palsy with appropriate Lyme antimicrobial therapy when Lyme is established.
25. Supportive management of neurologic deficits alongside antimicrobial therapy.

Reference: IDSA/AAN/ACR Lyme guideline.

26. Oral doxycycline for appropriate outpatient Lyme carditis.
27. Oral amoxicillin for appropriate Lyme carditis.
28. Oral cefuroxime axetil for appropriate Lyme carditis.
29. Azithromycin as an alternative oral carditis agent.
30. IV ceftriaxone for hospitalized Lyme carditis.
31. Transition from IV ceftriaxone to oral antibiotics after clinical improvement.
32. 14–21 total days of antibiotic treatment for Lyme carditis.
33. Hospitalization and continuous ECG monitoring for severe carditis.
34. Temporary cardiac pacing for symptomatic severe bradycardia/high-grade block when required.
35. Avoiding unnecessary permanent pacemaker implantation when conduction abnormalities are expected to resolve with Lyme treatment.

Reference: Lantos PM, et al. IDSA/AAN/ACR guideline. Hospitalized carditis is generally initially treated with IV ceftriaxone, followed by oral therapy after improvement; temporary rather than permanent pacing is recommended when pacing is required.

36. 28 days of oral antibiotic therapy for initial Lyme arthritis.
37. Doxycycline for Lyme arthritis.
38. Amoxicillin for Lyme arthritis.
39. Cefuroxime axetil for Lyme arthritis.
40. A second oral antibiotic course in selected patients with partial response — a possible approach, not mandatory.
41. IV ceftriaxone for arthritis with minimal/no response to initial oral treatment.
42. 2–4 weeks of IV ceftriaxone in selected refractory Lyme arthritis.
43. NSAIDs for residual inflammatory joint symptoms when clinically appropriate.
44. Rheumatology evaluation for post-antibiotic Lyme arthritis.
45. DMARD therapy for post-antibiotic inflammatory Lyme arthritis in selected patients after adequate antimicrobial treatment.
46. Hydroxychloroquine in selected post-antibiotic inflammatory arthritis under specialist management.
47. Methotrexate in selected post-antibiotic Lyme arthritis.
48. TNF-inhibitor therapy in exceptional refractory post-antibiotic inflammatory arthritis under rheumatology supervision.
49. Intra-articular corticosteroid treatment in selected post-antibiotic inflammatory arthritis.
50. Arthroscopic synovectomy for selected persistent post-antibiotic Lyme arthritis.

The key distinction is that items 43–50 address persistent inflammation after adequate antimicrobial treatment, rather than treating Borrelia itself. Initial Lyme arthritis receives 28 days of oral antibiotics; patients with little response can receive IV ceftriaxone.

51. Single-dose doxycycline post-exposure prophylaxis — for qualifying high-risk Ixodes bites when given within 72 hours of tick removal. This prevents Lyme disease rather than treating established infection.
52. Prompt tick removal — reduces the probability of transmission and is an important preventive intervention.
53. Evaluation for reinfection — a new EM after successful previous treatment can represent a new infection and should not automatically be interpreted as persistence of the original infection.
54. Evaluate for Anaplasma coinfection — particularly with fever, leukopenia, thrombocytopenia or other suggestive findings.
55. Doxycycline when Lyme plus Anaplasma/Ehrlichia coinfection is suspected — doxycycline provides important coverage for these infections.
56. Evaluate separately for babesiosis — Babesia is a protozoan and requires different therapy; Lyme antibiotics such as doxycycline do not constitute adequate babesiosis treatment.
57. Symptom-directed management after treated Lyme disease — fatigue, pain, sleep disturbance and cognitive complaints deserve evaluation for both post-treatment Lyme disease symptoms and alternative/treatable diagnoses. CDC describes the science surrounding prolonged symptoms as limited, emerging and unsettled.
58. Rehabilitation/physical therapy — particularly for deconditioning, persistent musculoskeletal dysfunction or recovery after neurologic/articular disease.
59. Additional antibiotics when there is objective evidence of active/recurrent Lyme disease — for example, objectively documented arthritis, meningitis or neuropathy may justify further disease-specific assessment/treatment. By contrast, IDSA/AAN/ACR recommends against additional antibiotics solely for nonspecific fatigue, pain or cognitive symptoms after recommended therapy when there is no objective evidence of reinfection or treatment failure.
60. Investigational/persistent-Borrelia approaches — laboratory research has examined drug combinations against stationary-phase/persister B. burgdorferi, including combinations involving daptomycin + cefoperazone + doxycycline. These experiments are scientifically interesting but in-vitro activity does not establish clinical effectiveness or safety in humans with persistent symptoms. ILADS takes a different position from IDSA/AAN/ACR regarding longer and individualized antibiotic treatment for persistent manifestations, while acknowledging risks of long-term antibiotics.

The major controversy

There are two materially different schools of clinical guidance. The IDSA/AAN/ACR guideline recommends defined courses—such as 10 days doxycycline for uncomplicated EM, 14–21 days for many neurologic manifestations/carditis, and 28 days for arthritis—and recommends against additional antibiotics for persistent nonspecific symptoms without objective evidence of active disease.

ILADS advocates substantially more individualized decision-making and recommends longer initial therapy in some circumstances, including 4–6 weeks for most patients with EM in its 2024 statement and individualized decisions about additional treatment for persistent manifestations. These recommendations are controversial and differ significantly from CDC/IDSA/AAN/ACR recommendations.